Varol, I. Et Al. 2021. Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells. Current Pharmaceutical Analysis , vol.17, no.10 , 1272-1281.

Varol, I., KAPLAN, O., Erdoğar, N., Öncül, S., Nielsen, T. T., ERCAN, A., ... BİLENSOY, E.(2021). Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells. Current Pharmaceutical Analysis , vol.17, no.10, 1272-1281.

Varol, Işıl Et Al. "Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells," Current Pharmaceutical Analysis , vol.17, no.10, 1272-1281, 2021

Varol, Işıl Et Al. "Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells." Current Pharmaceutical Analysis , vol.17, no.10, pp.1272-1281, 2021

Varol, I. Et Al. (2021) . "Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells." Current Pharmaceutical Analysis , vol.17, no.10, pp.1272-1281.

@article{article, author={Işıl Varol Et Al. }, title={Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells}, journal={Current Pharmaceutical Analysis}, year=2021, pages={1272-1281} }